ArticleEndocrine, metabolic & immune disorders drug targets2025
Contribution of Type 2 Diabetes Susceptible Gene GCKR Polymorphisms Rs780094 and Rs1260326 to Gestational Diabetes Mellitus: A Meta-Analysis.
Article in Endocrine, metabolic & immune disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of GCKR and GLIS3 gene polymorphisms with gestational diabetes mellitus: A case-control study.The Indian journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is still no conclusive understanding of whether the glucokinase regulator (GCKR) gene rs780094 and rs1260326 polymorphisms predispose to gestational diabetes mellitus (GDM).
objectiveThis systematic review and meta-analysis aimed to determine the effect of the GCKR polymorphisms on GDM susceptibility.
methodsSeven literature databases were searched (from inception to February 17, 2024) to locate relevant studies included in further meta-analysis. Odds ratio (OR) and 95% confidence intervals (CI) in the pooled population were estimated to assess the effects of the variant allele on GDM risk.
resultsFor the rs780094 polymorphism, 13 datasets with 3443 GDM cases and 5930 nondiabetic controls were included. The pooled estimates in the allele model (OR: 1.19, 95% CI: 1.07~1.32), homozygote model (OR: 1.27, 95% CI: 1.10~1.47), dominant model (OR: 1.16, 95% CI: 1.03~1.31), and recessive model (OR: 1.31, 95% CI: 1.09~1.57) suggested that the C allele carriers were prone to GDM. For the rs1260326 polymorphism, five datasets with 1495 cases and 2678 controls were integrated. The statistically significant effect of the C allele was evident in the allele model (OR: 1.12, 95% CI: 1.01~1.24) and the homozygote model (OR: 1.26, 95% CI: 1.03~1.54).
conclusionThis meta-analysis suggested that the C allele of the rs780094 and rs1260326 polymorphisms in the GCKR gene are significantly associated with increased risk of GDM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.